Generic Name and Formulations:
Polyethylene glycol 3350 200g, sodium sulfate 15g, sodium chloride 5.38g, potassium chloride 2.03g, ascorbic acid 9.4g, sodium ascorbate 11.8g; per 2L of soln; pwd for reconstitution; contains phenylalanine 131mg/treatment; lemon-flavor.
Bausch Health Companies Inc.
Indications for MOVIPREP:
Bowel cleansing before colonoscopy.
No solid food from start of prep. No clear liquids at least 2hrs before colonoscopy. For both regimens start the evening before colonoscopy. Split-dose regimen: drink 240mL every 15 mins over 1hr until 1L consumed, follow with 480mL of clear liquid; in the AM (start ≥3.5hrs before colonoscopy), drink 2nd liter over 1hr, then drink 480mL of clear liquid at least 2hrs before colonoscopy; or, Evening-only regimen: start at least 3.5hrs before bedtime; drink 240mL every 15 mins over 1hr until 1L consumed, then drink 2nd liter 1.5hrs later over 1hr; in addition, drink 1L of clear liquid.
<18yrs: not established.
GI obstruction. Bowel perforation. Gastric retention. Ileus. Toxic colitis or megacolon.
Correct fluid/electrolyte abnormalities before use. Hyponatremia. History of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF, cardiomyopathy, or electrolyte imbalance: increased risk of arrhythmias; consider ECGs at pre-dose and post-colonoscopy. History or risk of seizures. Renal impairment; perform baseline and post-colonoscopy electrolytes, creatinine, BUN. Inflammatory bowel disease. Rule out suspected GI obstruction/perforation before administering. Severe ulcerative colitis. Impaired gag reflex. Risk of regurgitation or aspiration. G6PD deficiency. Phenylketonuria. Maintain adequate hydration. Pregnancy. Nursing mothers.
Caution with drugs that increase risk of fluid/electrolyte abnormalities, renal impairment, seizures, arrhythmias, or QT prolongation. Drugs that may lower the seizure threshold (eg, tricyclic antidepressants), alcohol or benzodiazepine withdrawal, known or suspected hyponatremia: may increase risk of seizures. Concomitant diuretics, ACE inhibitors, ARBs, NSAIDs; may affect renal function. Concomitant stimulant laxatives: not recommended; may increase risk of mucosal ulceration, ischemic colitis. Oral drugs administered within 1hr of start of MoviPrep may not be absorbed.
Malaise, nausea, vomiting, abdominal distension and pain (give slowly or discontinue if occurs), anal discomfort, thirst, sleep disorder, rigors, hunger, dizziness; hypersensitivity reactions; rare: arrhythmias, seizures.
Carton—1 (disposable container w. 4 pouches)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Ketogenic Diet as an Adjunct to Cancer Treatment
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Blinatumomab-Ponatinib Salvage Therapy in B-Cell Acute Lymphoblastic Leukemia: Case Report of Benefit
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer